VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
+30.09%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$944M
AUM Growth
–
Cap. Flow
+$944M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
61.64%
Holding
48
New
48
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$105M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$89.2M |
| 3 |
Ascendis Pharma
ASND
|
$78.7M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$58.1M |
| 5 |
Soleno Therapeutics
SLNO
|
$52.3M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$13.8B
| $105M | 11.17% | +800,000 | New | +$105M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $89.2M | 9.45% | +725,000 | New | +$89.2M |
|
|
3
Ascendis Pharma
ASND
$11.8B
| $78.7M | 8.34% | +625,000 | New | +$78.7M |
|
|
INBX
4
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $58.1M | 6.16% | +1,530,000 | New | +$58.1M |
|
|
5
Soleno Therapeutics
SLNO
$3.6B
| $52.3M | 5.54% | +1,300,000 | New | +$52.3M |
|
6
Merck
MRK
$210B
| $43.6M | 4.62% | +400,000 | New | +$43.6M |
|
7
Globus Medical
GMED
$8.27B
| $42.6M | 4.52% | +800,000 | New | +$42.6M |
|
8
Pacira BioSciences
PCRX
$1.2B
| $40.5M | 4.29% | +1,200,000 | New | +$40.5M |
|
|
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
| $38.4M | 4.07% | +1,625,000 | New | +$38.4M |
|
10
Vaxcyte
PCVX
$4B
| $33M | 3.49% | +525,000 | New | +$33M |
|
11
Insmed
INSM
$28.8B
| $27.9M | 2.95% | +900,000 | New | +$27.9M |
|
12
uniQure
QURE
$896M
| $26.6M | 2.82% | +3,925,000 | New | +$26.6M |
|
13
ALX Oncology
ALXO
$62.7M
| $24.6M | 2.61% | +1,655,000 | New | +$24.6M |
|
14
Immatics
IMTX
$619M
| $22.1M | 2.34% | +2,100,000 | New | +$22.1M |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $21.8M | 2.31% | +1,000,000 | New | +$21.8M |
|
16
Revolution Medicines
RVMD
$7.1B
| $20.8M | 2.2% | +725,000 | New | +$20.8M |
|
17
Biogen
BIIB
$19.4B
| $19.4M | 2.06% | +75,000 | New | +$19.4M |
|
18
Edwards Lifesciences
EW
$47.8B
| $17.2M | 1.82% | +225,000 | New | +$17.2M |
|
19
AstraZeneca
AZN
$248B
| $16.8M | 1.78% | +250,000 | New | +$16.8M |
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $16M | 1.7% | +450,000 | New | +$16M |
|
21
Lyra Therapeutics
LYRA
$11.5M
| $15.7M | 1.67% | +3,000,000 | New | +$15.7M |
|
22
Sanofi
SNY
$121B
| $14.9M | 1.58% | +300,000 | New | +$14.9M |
|
23
Nuvalent
NUVL
$5.52B
| $14.7M | 1.56% | +200,000 | New | +$14.7M |
|
24
Applied Therapeutics
APLT
$71M
| $13.9M | 1.47% | +4,155,000 | New | +$13.9M |
|
25
Liquidia Corp
LQDA
$2.38B
| $12.3M | 1.31% | +1,025,000 | New | +$12.3M |
|